A detailed history of Tower Research Capital LLC (Trc) transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 15,261 shares of AIM stock, worth $3,510. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,261
Previous 26,728 42.9%
Holding current value
$3,510
Previous $9,000 55.56%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.24 - $0.42 $2,752 - $4,816
-11,467 Reduced 42.9%
15,261 $4,000
Q2 2024

Aug 13, 2024

BUY
$0.35 - $0.61 $2,990 - $5,212
8,545 Added 46.99%
26,728 $9,000
Q1 2024

May 15, 2024

SELL
$0.33 - $0.48 $235 - $342
-714 Reduced 3.78%
18,183 $8,000
Q4 2023

Feb 13, 2024

BUY
$0.4 - $0.56 $7,188 - $10,064
17,972 Added 1942.92%
18,897 $8,000
Q3 2023

Nov 14, 2023

SELL
$0.44 - $0.71 $1,698 - $2,740
-3,860 Reduced 80.67%
925 $0
Q2 2023

Aug 14, 2023

BUY
$0.4 - $0.67 $1,170 - $1,960
2,926 Added 157.4%
4,785 $3,000
Q1 2023

May 09, 2023

BUY
$0.32 - $0.77 $530 - $1,276
1,658 Added 824.88%
1,859 $1,000
Q1 2022

May 12, 2022

SELL
$0.67 - $1.18 $3,129 - $5,511
-4,671 Reduced 95.87%
201 $0
Q4 2021

Feb 14, 2022

BUY
$0.92 - $1.96 $4,482 - $9,549
4,872 New
4,872 $4,000
Q3 2021

Nov 15, 2021

SELL
$1.91 - $2.17 $18,590 - $21,120
-9,733 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$1.93 - $2.39 $18,784 - $23,261
9,733 New
9,733 $21,000
Q1 2021

May 17, 2021

SELL
$1.88 - $2.82 $23,524 - $35,286
-12,513 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$1.68 - $2.45 $21,021 - $30,656
12,513 New
12,513 $22,000

Others Institutions Holding AIM

About AIM ImmunoTech Inc.


  • Ticker AIM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,049,300
  • Market Cap $11.1M
  • Description
  • AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...
More about AIM
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.